Skip to main content

Congenital Hemophilia A

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
NCT06738485 | PHASE 3 | INTERVENTIONAL

For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than \[\<\] 1%).

Trial Information
10 Sites
60 Participants
RECRUITING
to 65 Years

If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

The Second Hospital of Anhui Medical University
Hefei,Anhui,China,230000
Beijing Children's Hospital
Beijing,Beijing,China,100045
Fujian Medical University Union Hospital
Fuzhou,Fujian,China,350001
Guangzhou Women and Children's Medical Center
Guangzhou,Guangdong,China,510623
Nanfang Hospital of Southern Medical University
Guangzhou,Guangdong,China,510623
Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin,Hebei,China,300020
Hunan Provincial Children's Hospital
Changsha,Hunan,China,410021
XuZhou Children's Hospital
Xuzhou,Jiangsu,China,221006
Quinghai Provincial People's Hospital
Xining,Qinghai,China,81000
Qingdao Women and Children's Hospital
Qingdao,Shandong,China,266071

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov